---
title: "ALPHAMAB-B: JSKN003 has been granted FTD by the U.S. FDA for the treatment of PROC"
description: "ALPHAMAB-B announced that its drug JSKN003 has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal c"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262921970.md"
published_at: "2025-10-27T14:06:03.000Z"
---

# ALPHAMAB-B: JSKN003 has been granted FTD by the U.S. FDA for the treatment of PROC

> ALPHAMAB-B announced that its drug JSKN003 has received Fast Track Designation (FTD) from the U.S. FDA for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. This milestone marks the progress of JSKN003's global development. In addition, JSKN003 has also received approval for Phase II clinical trials and has been granted Breakthrough Therapy Designation for PROC and colorectal cancer. The Phase III clinical trial of the drug is progressing smoothly in China

According to the Zhitong Finance APP, ALPHAMAB-B (09966) announced that JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (collectively referred to as PROC) regardless of human epidermal growth factor receptor 2 (HER2) expression levels. This marks another important milestone in the global development process of JSKN003.

In addition, JSKN003 has received FDA approval to conduct a Phase II clinical trial for PROC regardless of HER2 expression levels, and has been granted Breakthrough Therapy Designation by the National Medical Products Administration (NMPA) for both PROC and colorectal cancer (CRC), as well as Orphan Drug Designation by the FDA for gastric/gastroesophageal junction cancer (GC/GEJ). Furthermore, the Phase III clinical trial of JSKN003 for PROC regardless of HER2 expression levels is progressing smoothly in China. The granting of FTD further underscores the confidence of international regulatory agencies in the clinical potential of JSKN003 and its importance as a novel therapeutic candidate

### Related Stocks

- [09966.HK - ALPHAMAB-B](https://longbridge.com/en/quote/09966.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 隨着公司推進更優越的 ALS 療法，Coya Therapeutics 的股票有望升值 | Coya Therapeutics (COYA) 是一家臨牀階段的生物科技公司，正在推進其主要候選藥物 COYA 302，用於治療肌萎縮側索硬化症（ALS）和額顳葉痴呆（FTD），該藥物利用低劑量白介素-2 來對抗神經炎症。公司與 Dr.  | [Link](https://longbridge.com/en/news/275894413.md) |
| 忘掉 AI 股票：這家制藥巨頭正在通過 AI 主導藥物研發 | 而且還有多種方式可以將這項技術變現 | [Link](https://longbridge.com/en/news/276017486.md) |
| Nuclera 與 leadXpro 合作，加速複雜膜蛋白的結構性藥物設計 | Nuclera 和 leadXpro 宣佈建立合作伙伴關係，以增強複雜膜蛋白的基於結構的藥物設計。這一合作結合了 Nuclera 的 eProtein Discovery 技術和 leadXpro 的 AI/ML 驅動的專業知識，創建了一個 | [Link](https://longbridge.com/en/news/276109364.md) |
| 根據 Valuates Reports 的報告，到 2031 年，生物技術市場的 ETAI 規模預計將達到 19.71 億美元 | 全球生物技術領域的人工智能市場預計將從 2024 年的 10.33 億美元增長到 2031 年的 19.71 億美元，年均增長率為 10.6%。主要增長驅動因素包括基於平台的藥物發現、機器學習應用以及多模態數據的整合。生成式人工智能在化合物 | [Link](https://longbridge.com/en/news/276147064.md) |
| 研究發現，在懷孕期間停止使用抗抑鬱藥可能會增加心理健康風險 | 一項研究顯示，許多孕婦停止服用抗抑鬱藥，增加了嚴重心理健康危機的風險。心理健康問題是美國孕婦死亡的主要原因。研究發現，18% 的女性完全停止了藥物治療，65% 的女性中斷治療超過 60 天。停止治療的女性在心理健康危機方面面臨更高的風險，尤 | [Link](https://longbridge.com/en/news/275934391.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.